PLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protalix Biotherapeutics Inc (PLX) is not a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company's financial performance is poor, with significant revenue and net income declines, and there are no strong positive catalysts or trading signals to justify an immediate investment. The technical indicators suggest the stock is oversold, but the lack of strong growth prospects and weak sentiment make it unsuitable for long-term investment at this time.
The stock is oversold with an RSI of 19.207, indicating potential for a short-term bounce. However, the MACD histogram is negative and expanding (-0.092), signaling bearish momentum. The stock is trading near its support level (S1: 2.236), with resistance levels at R1: 2.931 and R2: 3.146. Moving averages are converging, showing no clear trend direction.
The European Commission's approval of Elfabrio's new dosing regimen, with projected 2026 revenues between $78 million and $83 million, is a potential positive catalyst.
The company reported a decline in FY 2025 product sales and missed EPS estimates. Financials show significant YoY declines in revenue (-97.65%), net income (-100%), and gross margin (-1344.71%). There is no recent congress trading data or insider/hedge fund activity to suggest confidence in the stock.
Protalix Biotherapeutics reported a significant decline in financial performance for 2025/Q4, with revenue dropping by 97.65% YoY, net income falling to zero, and EPS declining by 233.33%. Gross margin also dropped drastically, indicating poor operational efficiency.
No recent analyst rating or price target changes are available for Protalix Biotherapeutics Inc.
